Biomarin Drug Fails To Show Benefit In Inattention, Mood Complications Among Patients with PAH Deficiency

A new drug developed by Biomarin Pharmaceuticals Inc. showed promise in lowering phenylalanine in the blood of patients with phenylalanine hydroxylase deficiency. However, it failed to show benefit in mood complications and inattention.